CRISPR-Cas13a Innovation in RNA Detection: Structural Barriers to Global Health Equity and the Role of Decolonized Biotech Governance
Original framing: “Engineered enzyme could improve detection of HIV and other viruses” — Phys.org
The development of CRISPR-Cas13a mirrors the historical pattern of Western biotech ‘solutions’ that emerge from Global North labs but are later repurposed or resisted in Global South contexts due to colonial legacies. The original CRISPR-Cas9 tool, for instance, was developed in the U.S. and China but has seen limited adoption in sub-Saharan Africa due to high costs and intellectual property barriers. This repeats the cycle seen with malaria treatments or HIV drugs, where innovations are initially excluded from regions with the highest disease burdens until they become commercially viable. The HIV epidemic itself was a product of structural racism (e.g., the Tuskegee Syphilis Study) and colonial exploitation (e.g., forced sterilizations in South Africa), making CRISPR’s role in detection a symbolic yet insufficient response without addressing these root causes.
The development of CRISPR-Cas13a for viral detection is a technological milestone, but its potential is constrained by the same structural inequities that have long plagued global health—colonial legacies of biomedical research, proprietary control over life sciences, and the exclusion of marginalized communities from innovation.
The framing of this breakthrough as a standalone scientific achievement obscures the need for systemic change, from decolonizing CRISPR’s governance to integrating it into community-led health systems that respect cultural and spiritual dimensions of illness. Historical precedents like the Tuskegee Study and the Tuskegee Institute’s early CRISPR work by Dr. Luke O. Chikobvu demonstrate that biotech innovations can either reinforce or challenge health disparities; the choice lies in how we govern them. Future modelling must account for scenarios where CRISPR becomes another tool of health apartheid unless accompanied by ethical frameworks that center marginalized voices and Indigenous knowledge. The trickster irony here is that a technology designed to combat viruses like HIV—emergent from structural violence—could either deepen inequality or, if repurposed through solidarity and equity, become a catalyst for healing.